Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacogenomics draft guidance

Executive Summary

FDA is understood to be on track to release its pharmacogenomics draft guidance in August. The draft guidance is understood to state that FDA will not require sponsors to collect pharmacogenomics data for product applications (1"The Pink Sheet" April 14, 2003, p. 12). The Drug Information Association is planning a meeting on pharmacogenomics for November...

You may also be interested in...



Pharmacogenomic Data “Regulatory Impact” To Be Outlined In Guidance

The regulatory impact of different categories of pharmacogenomic data will be addressed in a draft guidance, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said at FDA's Science Board Advisory Committee meeting April 9

OTC Marketing Awards 2021– New Date, New Deadline, New Category

The OTC Marketing Awards 2021 will now take place on 1 December, with entries invited from activity in 2020 and 2021. A special award – Best COVID-19 initiative by an OTC Company – will also recognize the efforts made by the British consumer healthcare industry during the COVID-19 pandemic.

Ambitious Amryt To File Butterfly Skin Drug Imminently

The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel